Life Sciences Tools and Services
Company Overview of AltheaDx, Inc.
AltheaDx, Inc. operates as a molecular diagnostics company for pharmacogenetics (PGx) in the United States. The company’s algorithm-based bioinformatic platform and PGx product testing portfolio serve as a tool to assist healthcare providers in identifying optimal drugs for patients, as well as dosing guidelines based on a patient’s genetic make-up, current prescription regimen, and other key factors. Its IDgenetix test enables personalized therapeutic decisions for patients suffering from prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders, and pains. The company also offers research and development services that provide a suite o...
10578 Science Center Drive
San Diego, CA 92121
Founded in 1998
Key Executives for AltheaDx, Inc.
Chief Executive Officer, President and Director
Co-Founder and Chairman of the Board
Senior Vice President Operations
Senior Vice President of Regulatory Affairs & Quality Assurance
Director of Biomarker Development
Compensation as of Fiscal Year 2016.
AltheaDx, Inc. Key Developments
AltheaDx Launches Next-Generation Sequencing Oncology Panel
Sep 21 15
AltheaDx, Inc. has launched AltheaDx Oncology Panel 150, a CLIA validated next-generation sequencing, or NGS, panel. This panel enables simultaneous testing of 143 solid tumor genes. The AltheaDx Oncology Panel 150 (AOP 150) Assay is a targeted, NGS assay for drug and companion diagnostic development programs. The AOP 150 Assay is based on Thermo Fisher Scientific's Oncomine Comprehensive Assay. It runs on the proven Ion Torrent NGS technology, includes the Ion AmpliSeq library preparation technology, and leverages the Oncomine Knowledgebase, which is one of the collections of oncology data long-trusted by pharmaceutical companies. The AOP 150 Assay is designed to work with minimal sample input per run and is well-suited for analysis of tumor samples extracted from formalin-fixed paraffin-embedded (FFPE) tissue, including small biopsies and fine needle aspirates. With a rapid turnaround time, the AOP 150 assay is capable of detecting thousands of clinically and pharmacologically relevant biomarkers, including single nucleotide somatic variants, insertions and deletions. The AOP 150 Assay is designed to enable pharmaceutical companies the ability to make evidence-based decisions as part of their clinical trial programs.
AltheaDx, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 08:30 AM
Jun 18 15
AltheaDx, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 08:30 AM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Greg Hamilton, Chief Executive Officer and Director.
AltheaDx, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015
Feb 22 15
AltheaDx, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 1, 2016
December 11, 2015